Adequacy of an evidence-based treatment guideline for complicated urinary tract infections in the Netherlands and the effectiveness of guideline adherence

  • V. Spoorenberg
  • J. M. Prins
  • E. E. Stobberingh
  • M. E. J. L. Hulscher
  • S. E. Geerlings
Article

DOI: 10.1007/s10096-013-1909-6

Cite this article as:
Spoorenberg, V., Prins, J.M., Stobberingh, E.E. et al. Eur J Clin Microbiol Infect Dis (2013) 32: 1545. doi:10.1007/s10096-013-1909-6

Abstract

Guideline recommendations on empirical antibiotic treatment are based on the literature, expert opinion, expected pathogens and resistance data, but their adequacy in the real-life setting is often unknown. We investigated the adequacy of the Dutch evidence-based guideline-recommended treatment options for patients with complicated urinary tract infections (UTIs) 2 years after guideline publication and, additionally, the adequacy of actually prescribed empirical therapy for patients treated with guideline-adherent versus non-guideline-adherent therapy. A retrospective, observational multicentre study in the Netherlands included 810 patients with a complicated UTI without special conditions and 174 with a urinary catheter. The susceptibility patterns of cultured uropathogens were compared with guideline-recommended treatment options, which included specific recommendations for patients with a catheter, and with actually prescribed empirical therapy. We considered inadequate coverage rates below 10 % as acceptable. Of the recommended regimens for patients with a UTI without other conditions, only the guideline-recommended combination of amoxicillin–gentamicin was acceptable (inadequate coverage rate 6 %). For patients with a catheter, inadequate coverage rates of recommended regimens ranged from 3 to 24 %. In patients with a UTI without other conditions, actually prescribed guideline-adherent therapy resulted in less broad-spectrum but not in less adequate therapy; in patients with a catheter, actually prescribed guideline-adherent therapy resulted in a higher coverage rate than those prescribed non-guideline-adherent therapy. Due to the continuously changing resistance rates and differences between the epidemiologies of uropathogens assumed in the guideline and those in real life, regular real-life assessments of recommended treatment options are necessary. Guideline adherence seems to be effective for increasing coverage rates without prescribing unnecessarily broad regimens.

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • V. Spoorenberg
    • 1
  • J. M. Prins
    • 1
  • E. E. Stobberingh
    • 2
  • M. E. J. L. Hulscher
    • 3
  • S. E. Geerlings
    • 1
  1. 1.Department of Internal Medicine, Division of Infectious Diseases, Centre for Infection and Immunity Amsterdam (CINIMA)Academic Medical CentreAmsterdamThe Netherlands
  2. 2.Department of Medical Microbiology, Care and Public Health Research Institute (CAPHRI)Maastricht University Medical CentreMaastrichtThe Netherlands
  3. 3.Scientific Institute for Quality of HealthcareRadboud University Nijmegen Medical CentreNijmegenThe Netherlands